Physician profile
Rashmi Thapa
NPI 1962663815
$5,826.46
in general payments reported to CMS, 2019-2025
12 companies · $773 in 2025
The $773 reported for 2025 was more than what 76% of Adult Congenital Heart Disease providers received nationally (typical 2025 total: $272).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,477 · 2020: $18.11 · 2021: $31.95 · 2022: $1,526 · 2025: $773.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $773.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $773.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,963.80 | 2019-2020 | |
| Boston Scientific Corporation | $1,848.22 | 2019-2025 | General - Vascular Access |
| Medtronic, INC. | $1,494.40 | 2022 | |
| Abiomed | $216.65 | 2025 | |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Angiodynamics, INC. | $44.48 | 2025 | Alphavac |
| Amgen INC. | $27.75 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $27.44 | 2019-2021 | |
| Abbott Laboratories | $18.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $17.00 | 2022 | |
| Allergan, INC. | $13.92 | 2019 | |
| Sanofi-Aventis U.S. LLC | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rashmi Thapa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.